|
INVERSEON is dedicated to utilizing the scientific discovery of our founder,
Dr. Richard Bond, by using inverse agonism at the beta-2 (β2) receptor to treat
obstructive lung diseases through enhanced safety and efficacy of bronchodilators
and through the prevention and reversal of mucous cell metaplasia and the associated
signs and symptoms of chronic cough.
INVERSEON has identified a subset of β blockers (inverse beta agonists) with pharmacological activity that down-regulate the intrinsic
pro-inflammatory constitutive actions of β2 receptors. Our initial targets include
obstructive lung diseases marked by chronic cough induced by mucous metaplasia and
hypersecretion. Appropriate targets, based on the histopathology, physiology, clinical
development pathway, regulatory precedent and commercial opportunity include:
- Aid to smoking cessation when added to standard of care either alone or as combination product
- Reducing signs and symptoms of chronic bronchitis with long-term benefits based on follow-up studies
- Asthma, especially in patients with cough and sputum.
Other conditions, including bronchiectasis and cystic fibrosis will also be tested.
INVERSEON holds a proprietary patent position on the use of inverse agonists to treat
obstructive lung diseases, using oral or inhaled inverse agonists.
|
